Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutationsdoi:10.1158/1538-7445.AM2019-442Oncogenic TRKA/B/C fusions are identified in multiple cancer types in adults and children. TRK inhibitors (TRKis)...
论文标题:NTRK fusion-positive cancers and TRK inhibitor therapy 作者:Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon 期刊:Nature Reviews Clinical Oncology 发表时间:2018/10/17 数字识别码:10.1038/s41571-018-0113-0 摘要:NTRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the ...
参考文献: [1]Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy:ASCO Guideline Update Bryan J. Schneider, Jarushka Naidoo, Bianca D. Santomasso, Christina Lacchetti, Sh...
clinical trial of the selective TRK inhibitor larotrectinib, and the treatment was started in June 2018. After 2 months of treatment, a CT scan revealed stable disease according to RECIST1.1 (Fig.3d). To our knowledge, this is a rare report on the clinical response to larotrectinib in ...
After careful consideration and discussion, the patient was amenable to trying the other NTRK inhibitor, larotrectinib, which he tolerated much better with limited toxicities. This patient is one of only a few who have been treated and the only known case report of both TRK inhibitors being ...
Zurletrectinib is active against 1st-generation TRK inhibitor resistance mutations in vitro Selitrectinib and repotrectinib are both next-generation TRK inhibitors specifically developed to maintain activity against on-target mutations that are acquired on progression to 1st-generation TRK inhibitors. ...
Additionally, the TRK inhibitor larotrectinib is actually under investigation as single-agent in a phase II NAVIGATE basket trial on NTRK fusion-positive solid cancers, including advanced CCAs (NCT02576431). Moreover, secondary mutations following treatment with TRK inhibitors may cause resistance to...
GNF-5837 is a potent pan-Trk inhibitor. GNF-5837 displays antiproliferative effects in cellular Ba/F3 assays (IC50 values are 7, 9 and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively). Exhibits selectivity for Trk receptors over a range of kinas...
The tumor-agnostic TRK inhibitor larotrectinib showed sustained antitumor activity in adult and pediatric patients withTRKfusionpositive cancers, based on updated findings from an integrated analysis of an adult phase I trial, the phase I/II SCOUT pediatric trial, and the phase II adult/adoles...
第15卷 第12 期 2017 年 12 月 临床药物治疗杂志 Clinical Medication Journal Vol.15,No.12 Dec,2017 新药咨讯 国家应急防控药物工程技术研究中心 学术支持 Trk 小分子激酶抑制剂研究进展 2017 年 12 月下旬,拜耳公司和 Loxo Oncology 公司合作开发的口服选 择性原肌球蛋白相关激酶 (Tropomyo- sin-related ...